Sugi Predict

Sugi Predict / Compounds / SCHEMBL182719

SCHEMBL182719

SCHEMBL182719

Clc1nc(Cl)c2cc(Br)ccc2n1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.68
▸ NT5E P21589 1/20 0.50
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46
▸ BCHE P06276 5/20 0.42
▸ ACHE P22303 5/20 0.42
▸ GRIN1 Q05586 5/20 0.42
▸ GRIN2A Q12879 5/20 0.42
▸ DHODH Q02127 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ GAA P10253 1/20 0.40
▸ MAPT P10636 1/20 0.39
▸ CASP3 P42574 1/20 0.39
▸ AVPR1A P37288 1/20 0.38
▸ MPO P05164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29487354 0.84 HTT (0.53) HTTNT5ECYP1A2CYP2D6CYP2C9
SCHEMBL2424537 0.84 HTT (0.53) HTTNT5ECYP1A2CYP2D6CYP2C9
SCHEMBL12575803 0.81 HTT (0.64) HTTNT5ECYP1A2CYP2D6CYP2C9
SCHEMBL8897424 0.81 HTT (1.00) HTTNT5ECYP1A2CYP2D6CYP2C9
SCHEMBL29623910 0.81 HTT (1.00) HTTNT5ECYP1A2CYP2D6CYP2C9
SCHEMBL3118975 0.81 RXFP1 (0.51) HTTNT5ECYP1A2CYP2D6CYP2C9
SCHEMBL27882458 0.79 HTT (0.62) HTTNT5ECYP1A2CYP2D6CYP2C9
SCHEMBL30013869 0.79 KDM4E (0.44) HTTCYP2C9BCHEACHEGRIN1
SCHEMBL405341 0.79 KDM4E (0.44) HTTCYP2C9BCHEACHEGRIN1
SCHEMBL30973214 0.78 HTT (0.65) HTTNT5ECYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637451-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-05-26 — — US disclosed
US-12582661-B2 Synthesis and application of class of respiratory syncytial virus inhibitors Shanghai Ark Biopharmaceutical Co., Ltd. (CN) 2026-03-24 — — US disclosed
US-12565511-B2 SOS1 inhibitor containing phosphorus CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2026-03-03 — — US disclosed
US-12497395-B2 Small molecule bromodomain inhibitors and uses therof CONVERGENE, LLC 2025-12-16 — — US disclosed
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 — — US disclosed
CN-120058795-A Phosphorus-containing SOS1 inhibitors 正大天晴药业集团股份有限公司 2025-05-30 — — CN disclosed
CN-120058797-A Phosphorus-containing SOS1 inhibitors 正大天晴药业集团股份有限公司 2025-05-30 — — CN disclosed
CN-120058796-A Phosphorus-containing SOS1 inhibitors 正大天晴药业集团股份有限公司 2025-05-30 — — CN disclosed
US-20250145589-A1 PYRIDINE DERIVATIVE AND USE THEREOF SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) 2025-05-08 — — US disclosed
CN-118302418-B Aromatic heterocyclic compound and application thereof 中国科学院上海药物研究所 2025-05-02 — — CN disclosed
WO-2008152387-A1 QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2008-12-18 — — WO disclosed
WO-2008152387-A1 QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2008-12-18 — — WO disclosed
EP-1687002-A4 FUSED HETEROCYCLIC COMPOUNDS SYNTA PHARMACEUTICALS CORP (US) 2008-07-23 — — EP disclosed
WO-2008012326-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-31 — — WO disclosed
WO-2008012326-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-31 — — WO disclosed
EP-1618094-B1 SUBSTITUTED HETEROARYLS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INST FOR PHARM DISCOVERY INC (US) 2007-09-05 — — EP disclosed
EP-1687002-A1 FUSED HETEROCYCLIC COMPOUNDS Synta Pharmaceuticals Corporation (US) 2006-08-09 — — EP disclosed
US-20050250770-A1 Fused heterocyclic compounds LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2005-11-10 — — US disclosed
WO-2005046698-A1 FUSED HETEROCYCLIC COMPOUNDS SYNTA PHARMACEUTICALS, CORP. (US) 2005-05-26 — — WO disclosed
US-20050009817-A1 Substituted heteroaryls INSTITUTES FOR PHARMACEUTICAL DISCOVERY, L.L.C. 2005-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250770-A1 Fused heterocyclic compounds IL2, IL4, IL15 HTT 123/4885NT5E 4325/4885CYP1A2 219/4885
US-20050009817-A1 Substituted heteroaryls PTPRS, PTPRO, PTPRR HTT 241/4885NT5E 2364/4885CYP1A2 2095/4885
US-12565511-B2 SOS1 inhibitor containing phosphorus SOST, SOS1, SOS2 HTT 4713/4885NT5E 3793/4885CYP1A2 4182/4885
US-12497395-B2 Small molecule bromodomain inhibitors and uses therof BRD4, BRPF3, BICRA HTT 702/4885NT5E 4192/4885CYP1A2 4830/4885
US-20250145589-A1 PYRIDINE DERIVATIVE AND USE THEREOF KRAS, NRAS, BRAF HTT 4112/4885NT5E 4272/4885CYP1A2 2493/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK HTT 4827/4885NT5E 2882/4885CYP1A2 4595/4885
US-12637451-B2 Amino quinazoline derivatives as P2X3 inhibitors P2RX3, P2RX1, P2RX7 HTT 4228/4885NT5E 271/4885CYP1A2 877/4885
US-12582661-B2 Synthesis and application of class of respiratory syncytial virus inhibitors SNU13, TMPRSS11D, SPTBN1 HTT 3829/4885NT5E 4179/4885CYP1A2 2610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.